✦ LIBER ✦

Adjuvant High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Support for High-Risk Primary Breast Cancer: Results from the Italian National Registry

✍ Scribed by Pedrazzoli, Paolo; Martinelli, Giovanni; Gianni, Alessandro Massimo; Da Prada, Gian Antonio; Ballestrero, Alberto; Rosti, Giovanni; Frassineti, Giovanni Luca; Aieta, Michele; Secondino, Simona; Cinieri, Saverio; Fedele, Roberta; Bengala, Carmelo; Bregni, Marco; Grasso, Donatella; De Giorgi, Ugo; Lanza, Francesco; Castagna, Luca; Bruno, Barbara; Martino, Massimo

Book ID: 122144039
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 467 KB
Volume: 20
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2013.12.569

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

94 P - Paclitaxel containing high-dose c

94 P - Paclitaxel containing high-dose chemotherapy and autologous blood stem cell support for high risk primary breast cancer

✍ H.T. Greinix; W. Linkeach; M. Seifert; E. Kubista; K. Czerwendka; S.A. Brugger; 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 180 KB

High dose chemotherapy with autologous s

High dose chemotherapy with autologous stem cell support for the treatment of metastatic breast cancer

✍ Lois J. Ayash 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 416 KB 👁 1 views

247: High-Dose Chemotherapy with Autolog

247: High-Dose Chemotherapy with Autologous Stem-Cell Support Versus Standard-Dose Chemotherapy for High-Risk Breast Cancer: Meta-Analysis of Individual Patient Data from 15 Randomized Adjuvant Trials

✍ N.T. Ueno; D.A. Berry; M.M. Johnson; X. Lei; V.T. Lopez; J.A. Caputo; M. Bregni; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 50 KB

Randomized trial of high-dose chemothera

Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma : Follow-up at 12 years

✍ Emer O. Hanrahan; Kristine Broglio; Deborah Frye; Aman U. Buzdar; Richard L. The 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 163 KB 👁 1 views

P53 is the strongest predictor of surviv

P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support

✍ Manfred Hensel; Andreas Schneeweiss; Hans-Peter Sinn; Gerlinde Egerer; Erich Sol 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 129 KB 👁 3 views

## Abstract Our purpose was to determine the predictive value of tumor biologic parameters in patients with HRPBC who received HDCT with ASCT as first‐line treatment. From September 1992 to May 2000, 149 stage II or III HRPBC patients were enrolled in a single‐arm trial using a tandem HDCT regimen

The use of high-dose cyclophosphamide, c

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy

✍ Yee Chung Cheng; Gabriela Rondón; Ying Yang; Terry L. Smith; James L. Gajewski; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 274 KB